BioMimetic Therapeutics, Inc. (NASDAQ:BMTI)
The Company develops and commercializes bio-active drug-device combination products for the healing of musculoskeletal injuries and diseases, including periodontal, orthopedic, spine and sports injury applications.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
2gud2btrue
(< 20)
Submitted: 2/7/2012 9:54:49 AM :
Start Price:
$2.57
BMTI Score:
-4.07
Looking for entry at a favorable price it might pay off big time.
Recs
Haugurafpeningum
(85.94)
Submitted: 11/8/2011 2:31:18 AM :
Start Price:
$3.20
BMTI Score:
-28.14
Technical Monthly
Recs
p1a5244
(64.20)
Submitted: 9/18/2011 11:22:40 PM :
Start Price:
$4.01
BMTI Score:
-49.92
9/18/11 Options Predictor Rank #42. P/C Ratio 0.098 and Call Sizzle 2.628.
Recs
Recs
jiggernit
(99.77)
Submitted: 5/11/2011 3:17:17 PM :
Start Price:
$7.68
BMTI Score:
-65.99
I don't know why my time frame is set to three years... I think it's unlikely I would hold it that long.
Recs
KimLanners
(< 20)
Submitted: 5/10/2011 12:48:01 PM :
Start Price:
$8.73
BMTI Score:
+69.69
fda concerns
Recs
Trader2515
(< 20)
Submitted: 4/6/2011 10:45:23 AM :
Start Price:
$13.96
BMTI Score:
-81.32
BMTI's products are actually game changing in the market(s) they are addressing. Their products are at least as effective at bone and cartilage repair as conventional treatments, but with less invasive surgery required which results in faster recovery time for the patient. Oh, and the leadership at BMTI is made up of folks with very strong credentials. They've maintained solid VC backing and financials are increasingly looking good.
Recs
Recs
forbes10
(99.86)
Submitted: 6/25/2009 9:09:58 AM :
Start Price:
$9.87
BMTI Score:
-121.64
disruptive technology will turbocharge this stock
Recs
RNZ100
(93.32)
Submitted: 10/8/2008 8:28:03 PM :
Start Price:
$8.15
BMTI Score:
-106.24
Oversold (but then again, what isn't?!)
Recs
tiobueno
(99.28)
Submitted: 4/4/2008 12:40:33 PM :
Start Price:
$9.70
BMTI Score:
-74.56
April 1, 2008 11:00 AM EDT
BioMimetic Therapeutics Inc. (Nasdaq: BMTI) sees some concentrated insider buying:
CFO, Lawrence E. Bullock, bought 10,000 shares on 03/28
Officer, Earl Martin Douglas, bught 1,000 shares on 03/28
Director, Gary E Friedlender, bought 8,500 shares on 03/28
Director, James Murphy, bought 5,000 shares on 03/28
CEO, Samual E. Lynch, bought 5,400 shares on 03/28.
BioMimetic fell 56% last Thursday related to an FDA safety review of Regranex, a Johnson & Johnson product, which contains the same drug product (becaplermin) as BioMimetic's product candidates. [LJ]
Recs
TheTazzBot
(< 20)
Submitted: 4/3/2008 8:03:44 PM :
Start Price:
$9.51
BMTI Score:
-73.87
Expect this stock to climb back to its peak, or 80% of its peak in a few weeks
Recs
sigmanu00
(< 20)
Submitted: 4/3/2008 10:12:03 AM :
Start Price:
$8.76
BMTI Score:
-72.70
BMTI continues to grow and has extensive private investors to assist it in the provisions of cutting edge pharmaceuticals.
Recs
GerMax25
(< 20)
Submitted: 4/1/2008 11:17:44 AM :
Start Price:
$14.62
BMTI Score:
-85.44
Company unfairly bore the brunt of a minor, and arguably inapplicable minor FDA warning. At the current levels, it presents a rare opportunity to buy at a dirt cheap pps. I am looking for the stock to bounce back to the mid teens in the short term.
The company has a couple of great products in trials, with early trials showing great results. Should be a multi-bagger in a couple of years.
Recs
ETHERTON8409
(< 20)
Submitted: 3/28/2008 3:12:48 PM :
Start Price:
$8.65
BMTI Score:
-75.95
medical devicces when properly marketed will perform at very high levels of return
Recs
Recs
C141
(79.97)
Submitted: 6/8/2007 10:36:50 PM :
Start Price:
$17.66
BMTI Score:
-78.77
up and coming company
Recs
scoobyvol
(48.93)
Submitted: 2/20/2007 11:05:20 AM :
Start Price:
$16.90
BMTI Score:
-81.99
Great drugs coming down the pipeline.
Recs
mysocialsecurity
(< 20)
Submitted: 2/7/2007 3:27:43 PM :
Start Price:
$17.31
BMTI Score:
-82.73
Recent successful clinical results of bone graft tests, plus insider buying on top of already high inside ownership, make this stock attractive.
Recs
SH2F088
(85.43)
Submitted: 12/2/2006 3:56:09 AM :
Start Price:
$10.60
BMTI Score:
-77.05
Seems like a boom or bust biotech. Deutsche has an execellent track record, and they recently recommended BMTI at a higher price.
I am speculating that they are not wrong, I am just in at a better level. My guess is Deutsche liked the pipeline and the good earnings report pushed them over the edge into a buy rating, which gave the stock a pop. As a low liquidity stock, the price has since drifted down.
The good earning report is an indication that management is doing its job keeping burn rates in-line so that the company will survive until they get a breakthrough, or at least some hits.
If they do get a breakthrough, this will look like a genius move.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 20